男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Latest

Sinopharm's COVID-19 vaccine remained active against S.Africa variant: study

Updated: 2021-02-05 17:09
Share
Share - WeChat
A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, Sept 5, 2020. [Photo/Agencies]

Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.

Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.

Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralising activity against the South African variant, their researchers said in a paper.

The paper was written by researchers from Sinopharm-affiliated Beijing Institute of Biological Products, the Institute of Microbiology of Chinese Academy of Sciences, which is co-developing a candidate with Zhifei unit, and two other Chinese agencies.

However, the samples' activity against the variant was weaker than against the original virus and another variant currently spreading globally, according to the paper published on website BioRxiv ahead its peer-review.

The activity reduction "should be taken into account for its impact for the clinical efficacy of these vaccines," they said.

The Sinopharm vaccine is approved in China for general public use and is also used in several other countries including the United Arab Emirates. The Zhifei shot is in late-stage clinical trials in China and overseas.

Preliminary clinical trial data on vaccines from Novavax Inc and Johnson & Johnson also showed they were significantly less effective at preventing COVID-19 in trial participants in South Africa, where the potent new variant is widespread.

Reuters

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 南木林县| 湘西| 咸阳市| 柘荣县| 乌兰浩特市| 杭锦旗| 静宁县| SHOW| 昂仁县| 沭阳县| 叶城县| 宿松县| 泰和县| 金溪县| 绩溪县| 龙岩市| 浦城县| 昌图县| 汾阳市| 忻州市| 古交市| 新乡县| 海阳市| 柳林县| 左贡县| 元谋县| 永善县| 平果县| 上高县| 英吉沙县| 清涧县| 大英县| 咸丰县| 太和县| 大港区| 云南省| 孟津县| 乌审旗| 长沙县| 尉犁县| 酒泉市|